Neurology

Piero G. Antuono, MD

Professor of Neurology, Pharmacology, and Toxicology
Director of the Dementia Research Center

Specialty: Adult Neurology

Sub-Specialty:

• Neuropharmacology of Aging
• Alzheimer's Disease
• Dementia

Education:

Training:

Societies: 
 

Awards/Honors: 
 

Brief Clinical/Research Interest Statement:

Aging of the Brain and Dementia

Original Publications

1. Xie C, Li W, Chen G, Douglas Ward B, Franczak MB, Jones JL, Antuono PG, Li SJ, Goveas JS. The co-existence of geriatric depression and amnestic mild cognitive impairment detrimentally affect gray matter volumes: voxel-based morphometry study. Behav Brain Res 2012 Dec 1;235(2):244-50 PMID 22909988
2. Chen G, Ward BD, Xie C, Li W, Chen G, Goveas JS, Antuono PG, Li SJ. A clustering-based method to detect functional connectivity differences. Neuroimage 2012 May 15;61(1):56-61 PMID 22405733
3. Li W, Antuono PG, Xie C, Chen G, Jones JL, Ward BD, Franczak MB, Goveas JS, Li SJ. Changes in regional cerebral blood flow and functional connectivity in the cholinergic pathway associated with cognitive performance in subjects with mild Alzheimer's disease after 12-week donepezil treatment. Neuroimage 2012 Apr 2;60(2):1083-91 PMID 22245641
4. Goveas JS, Xie C, Ward BD, Wu Z, Li W, Franczak M, Jones JL, Antuono PG, Li SJ. Recovery of hippocampal network connectivity correlates with cognitive improvement in mild Alzheimer's disease patients treated with donepezil assessed by resting-state fMRI. J Magn Reson Imaging 2011 Oct;34(4):764-73 PMID 21769962
5. Xie C, Goveas J, Wu Z, Li W, Chen G, Franczak M, Antuono PG, Jones JL, Zhang Z, Li SJ. Neural basis of the association between depressive symptoms and memory deficits in nondemented subjects: resting-state fMRI study. Hum Brain Mapp 2012 Jun;33(6):1352-63 PMID 21618660
6. Goveas J, Xie C, Wu Z, Douglas Ward B, Li W, Franczak MB, Jones JL, Antuono PG, Yang Z, Li SJ. Neural correlates of the interactive relationship between memory deficits and depressive symptoms in nondemented elderly: resting fMRI study. Behav Brain Res 2011 Jun 1;219(2):205-12 PMID 21238490
7. Xu G, Antuono PG, Jones J, Xu Y, Wu G, Ward D, Li SJ. Perfusion fMRI detects deficits in regional CBF during memory-encoding tasks in MCI subjects. Neurology 2007 Oct 23;69(17):1650-6 PMID 17954780
8. Franczak M, Prost RW, Antuono PG, Mark LP, Jones JL, Ulmer JL. Proton magnetic resonance spectroscopy of the hippocampus in patients with mild cognitive impairment: a pilot study. J Comput Assist Tomogr 2007 Sep-Oct;31(5):666-70 PMID 17895774
9. Xu G, Xu Y, Wu G, Antuono PG, Hammeke TA, Li SJ. Task-modulation of functional synchrony between spontaneous low-frequency oscillations in the human brain detected by fMRI. Magn Reson Med 2006 Jul;56(1):41-50 PMID 16767759
10. Antuono PG, Jones JL, Wang Y, Li SJ. Alzheimer Disease: evaluation of a functional MR imaging index as a marker. (Li SJ, Li Z, Wu G, Zhang MJ, Franczak M, Antuono PG) Radiology 2002 Oct;225(1):253-9 PMID 12355013
11. ANTUONO, P.G., Jones, J, Beyer, J.  Alternative Medicine in the Elderly: Use and Abuse.  Elder's Advisor Vol 2 (3): 75-81, 2001.
12. ANTUONO, P.G., Beyer, J.  The Burden of Dementia, A Medical and Research Perspective.  Theoretical Medicine 20:3-13, 1999.
13. Williams, K., Rosen, A., Alexander, M., Hammeke, T., ANTUONO, P.G., Maas, E., DeYoe, A.:  The Perceptual Consequences of Cortical Retinotopy:  Functional Field Mapping in Human Subjects. Neuroimage (229-39) 1998, Vol 8.
14. ANTUONO, P.G., Doody, R., Gilman, S., Huff, J., Scheltens, P., Ueda, K., Khachaturian, Z.:  Diagnostic Criteria for Dementia in Clinical Trials; Position Paper from the International Working Group on Harmonization of Dementia Drug Guidelines.   Alzheimer Disease and Associated Disorders  vol. 11, suppl. 3, pp. 22-25, 1997.
15. Wong-Riley, M., ANTUONO, P.G., Ho, K-C., Egan, R., Hevner, R., Liebl, W., Hunag, Z., Rachel, R., Jones, J.:  Cytochrome Oxidase in Alzheimer's Disease:  Biochemical, Histochemical, and  Immunohistochemical Analyses of the Visual and other Systems.   Vision Res., vol. 37, no. 24, p. 3593-3608, 1997.
16. Decreased glutamate + glutamine in Alzheimer's disease detected in vivo with (1)H-MRS at 0.5 T. Neurology 2001 Mar 27;56(6):737-42 PMID 11274307
17. Huff FJ, Antuono PG, Delagandara JE, McDonald MA, Cutler NR, Cohen SR, Green RC, Zemlan FP, Crismon ML, Alter M, Shipley JE, Reichman WE. A treatment and withdrawal trial of besipirdine in Alzheimer disease. Alzheimer Dis Assoc Disord 1996;10(2):93-102 PMID 8727171
18. Huff, F.J., Alter, M., ANTUONO, P.G., et al. Preliminary Evaluation of Besipirdine for the Treatment of Alzheimer's Disease.   The Neurobiology of Alzheimer's Disease/Annals of the New York Academy of Sciences  vol. 777, p. 410-14, January 17 1996.
19. ANTUONO, P.G., Ravanelli-Meyer, J., Nicholson, K., Bloom, A. Leukocyte Hexokinase Activity in Aging and Alzheimer's Disease.  Dementia.  vol. 6, p. 200-204, 1995.
20. ANTUONO, P.G., Beyer, J. A Reason to Hope:  Linking Dementia Research, Care and Services in the 21st Century.  Wisconsin Medical Journal. vol. 94, p. 546-47, October, 1995.
21. Antuono PG. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group. Arch Intern Med 1995 Sep 11;155(16):1766-72 PMID 7654110
22. Antuono PG, Ravanelli-Meyer J, Nicholson K, Bloom AS. Leukocyte hexokinase activity in aging and Alzheimer disease. Dementia 1995 Jul-Aug;6(4):200-4 PMID 7550599
23. Beyer J., Moser S., ANTUONO, P.G.: Alzheimer Disease and Driving: The role of the Health Care Professional and Caregiver. Nicolini M. Ed. Pergamon Press. In Advances in the Biosciences, Pergamon Press, vol. 87, p. 7-8, 1993.
24. Pomara N., Deptula D., ANTUONO, P.G., Singh R., Ravanelli-Meyer J., Cooper T, Leviste F.:Leukocyte hexokinase activity in Alzheimer's disease. Pergamon Press. In Advances in the Biosciences, vol. 87, p. 201-203, 1993.
25. Ho KC, Gwozdz JT, Hause LL, Antuono PG. Correlation of neuronal cell body size in motor cortex and hippocampus with body height, body weight, and axonal length. Int J Neurosci 1992 Jul-Aug;65(1-4):147-53 PMID 1341676
26. ANTUONO, P.G., Tikofsky, R., Hellman, R., Saxena, V.:  SPECT in the assessment of dementia; Mind (4) 1: 6-8, 1990.
27. Saxena, V.K., ANTUONO, P.G., Tikofsky, R.S., Hellman, R.S.:  SPECT brain imaging:  applications in cerebrovascular disease; Mind (4) 1: 9-11, 1990.
28. Tikofsky, R.S., Saxena, V.K., ANTUONO, P.G., Hellman, R.S.:  Understanding Single Photon Emission Computed Tomography SPECT) brain imaging; Mind (4) 1: 3-5, 1990.

Books, Chapters and Reviews

1. Huff, F.J., ANTUONO, P.G., Murphy, M., et al.:  Potential Clinical Use of an Adrenergic-Cholinergic Agent (HP128) and the Treatment of Alzheimer's Disease.  In:  Aging and Alzheimer's Disease  (Growdon, J.H., Corkin, S., Ritter-Walker, E., eds)  New York Academy of Sciences, New York, NY.  263-267, 1991.
2. ANTUONO, P.G:, Korperstellung, Magnus R.:  Rosanoff and Franklicy Book Programs. pp. 801.  Book Review In:  J. Hist. of Medicine.  43:50-501, 1988.
3. ANTUONO, P.G.  Guns and Dementia  In  "Bridges", Dementia Care Network, Alzheimer's Association of S.E. Wisconsin, vol. 3, no. 4, Fall 1997.
4. ANTUONO, P.G.  In Memoriam, Luigi Amaducci, MD (1932-1998). Neurology 50:1513,1998.
5. Krouwer H, Barkhaus P, ANTUONO, P.G.  The Reflexes of Hoffmann, Trömner and Mayer. In Koehler, PJ, Bruyn GW, Pearce JMS (eds) Neurological Eponyms. Oxford Press, New York, 2000, 127-135.
6. ANTUONO, P.G.  Le Risposte Alla Malattia Di Alzheimer.  I Farmaci E La Riabilitazione Treviso. In Press.
7. Krouwer H, Barkhaus P, ANTUONO, P.G.  The Reflexes of Hoffmann, Trömner and Mayer. In: Neurological Eponyms (Koehler, P.J., Bruyn, G.W., Pearce J.M.S.) New York, Oxford, 127-135, 2000.
8. ANTUONO, P.G., Li, S.J., et al.  Functional MRI in Alzheimer's disease. In: Dementia: A Multidisciplinary Approach.  (Mangone C., Allegri R, Arizaga R, Ollari J. Eds). Editorial Medica Panamericana. In Press.
9. ANTUONO, P.G., Franczak M.  Lo Studio Sulle Suore Scolastiche Di Nostra Signora.   Fattori di Rischio per L'Alzheimer'.  L'Alzheimer 2000. Firenze Anno III. 12-14.
10. ANTUONO, P.G.  Prevenzione Delle Malattie Cerebrovasculari Riduce L'Alzheimer. Alzheimer 2000 Firenze. Anno III, 15-16.

Grants & Funding

Title: Safety and efficacy of MK-0966 for the prevention of Alzheimer's Disease.
Source:
Role: Principal Investigator (5% effort)
Dates: 1998-2001

Title: Gingko Biloba special extract Egb761 in dementia of the Alzheimer's type.  A double-blind multicenter study.
Source: W. Schabe GmbH and Company/Worldwide Clinical Trials.
Role: Principal Investigator (5% effort)
Dates: 1999-2001

Title: Independent life in the elderly (The Nun Study).
Source: National Institute of Health.
Role: Co-investigator (5% effort), Principal Investigator, Dr. Snowdon
Dates: 1996-2000

Title: Independent life in the elderly (The Nun Study).
Source: National Institute of Health.
Role: Subcontracted (10% effort),  Principal Investigator, Dr. Snowdon.
Dates: 1999-2001

Title: Functional MRI in Alzheimer's Disease.
Source: Cassie M. Bach Memorial Research Fund.
Role: Principal Investigator (5% effort)
Dates: 1998-2003

Title: Protocol 126-01 "The Safety and Efficacy of MK-0966 25 mg in Delaying the Progression of Symptoms of Alzheimer's Disease in Patients With Probable Alzheimer's Disease"
Source: IRC#00-151  HRRC#258-00.
Role:
Dates: 2000-2001

Title: MK-0966 for the Treatment of Mild Cognitive Impairment and Prevention of Conversion to Alzheimer's Disease
Source: HRRC#104-98  IRC#98-59.
Role: 5% effort.
Dates: 1999-2002

Title: Establishment of Community Based Multispecialty Clinics for Diagnosis and Management of Dementia.
Source: Helen Bader Foundation
Role: Principal Investigator (5% effort)
Dates: 2000-2001

Title: Neurological Exams in the Nun Study.
Source: Helen Bader Foundation.
Role: Principal Investigator. (pending)
Dates: 2000-2001

Title: (State Grant) Administration on Aging. Alzheimer's Disease Demonstrative Grant to States (90AZ2359)
Source:  Wisconsin State Department of Health & Family Services
Role:  Co-investigator P1
Dates:  2000-2003

Title: MR Spectroscopy in Alzheimer's Disease.  Pharmacological effects in mild cognitive impairment.
Source:
Role: Principal Investigator (5% effort)
Dates: 2000-2003

Title: Resting state in functional MRI.
Source: The Alzheimer's Association.
Role: Co-investigator (5% effort)
Dates: 2000-2003

Title: Alzheimer's Disease by functional MRI.
Source: The National Institute of Health.
Role: Co-investigator (25% effort)
Dates: 2000-2005

Title: Independent life in the elderly (The Nun Study).
Source: National Institute of Health.
Role: Subcontract: Neurological Examinations (10% effort),  PI, Dr. Snowdon.
Dates: 1999-2001

Title: Glen and Gertrude Humphrey Foundation Endowment for Research in Alzheimer's Disease
Source: Glen and Gertrude Humphrey Foundation
Role: Endowment To Dementia Center
Dates: 2001

Title: Management of Alzheimer's Disease
Source: Industry
Role: Organizer, Planner, Moderator, Presenter
Dates: February 10, 2001

Title: Epidemiology of Dementias In Africa
Nairobi, Kenya
Source: Industry
Role: Organizer
Dates: April 23 2001

Title: Future Trends in Dementia: Alzheimer's Disease International
 Christchurch, New Zealand
Source: Industry
Role: Organizer
Dates: October 27, 2001

Title: Creation of a Data portal of the Nun Study in Wisconsin
  (Pending for 1/1/01)
Source: Helen Bader Foundation.
Role: Principal Investigator (5% effort)
Dates: 2000-2001

Title: The Neurological Exam in the Nun Study (withdrawn)
Source: Helen Bader Foundation.
Role: Principal Investigator (5% effort)
Dates: 2000-2001

Title: An fMRI Index as a Risk Marker for Alzheimer's Disease (Pending)
Source: The National Institute of Health.
Role: Co-investigator (15% effort)
Dates: 2000-2005

Title: Mechanisms of an fMRI Index for Alzheimer's Disease (Pending)
Source: The National Institute of Health
Role: Co-Investigator (10% effort)
Dates: 2001-2003

Title: Drug Effects on an fMRI Marker in MCI (Pending)
Source: Janssen Pharmaceuticals
Role: Principle Investigator (5% effort)
Dates: 2001-2002

Title: Exelon in Mixed Dementia (Pending)
Source: Novartis Pharmaceutical
Role: Principle Investigator (5% effort)